A carregar...
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Progress in the development of new therapies for cystic fibrosis (CF) has benefitted from therapeutically responsive biomarkers to streamline drug development. Paradoxically, these response biomarkers have proven to be essential even in the presence of data demonstrating a lack of correlation with c...
Na minha lista:
| Publicado no: | Trends Mol Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708517/ https://ncbi.nlm.nih.gov/pubmed/32868171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmed.2020.08.002 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|